Apolipoprotein C
lipoproteinApolipoprotein C mediates lipid metabolism and HDL remodeling; its altered expression during plaque rupture and coronary events reflects changes in lipoprotein turnover.
Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleHDL apolipoprotein; altered in plaque rupture; lipid-metabolism marker.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I46
C — confounder / Type-II46
A — assay feasibility82
E — evidence strength20
T1DI (composite)8
Specificity differential (R−C)0
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Immunoturbidimetric/nephelometric; or NMR/ultracentrifugation for subfractions
Reagent / substrate
Anti-apolipoprotein antibody-latex; or NMR profile
Platform
Automated analyzer / NMR
Turnaround · availability
Routine–send-out · Variable
Literature evidence(2)
- Utility of discovery approach using proteomics to create a biomarker profile for coronary microvascular dysfunction.Microvascular research · 2020 · PMID 32007502 · doi
- The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture.Journal of proteomics · 2014 · PMID 24747125 · doi